October 2018 Issue Table Of Contents

From The Editor

• The Value Of First-Hand Experience

Feature Articles

• From Big To Specialty — The Operational Transformation Of Bristol-Myers Squibb
• Apellis Advances On Autoimmunity
• Bayer Corrals U.S. Bio Clusters On Both Coasts

Capitol Perspectives

• Rollout Begins Of Trump’s Drug Blueprint

Patient Perspectives

• Words Matter: At The Crossroads Of Innovation And Dignity

CEO Corner

• On Leadership

From Principles and Policy to Execution

• Succeeding With Evidence-Based Medicine Won’t Be Easy

Industry Research

• The Top 5 Selection Drivers For Phase IV Services

Companies To Watch

• Symbiotix Biotherapies

Inside The Industry

• Improving Diversity in Life Sciences: 4 Ways to Turn Outrage into Action
• Lessons Learned from A Biopharma Cybersecurity Attack
• Biopharma Pioneer Returns To Small Company Roots
• Serendipity: When Funders Found A Company
• What To Consider When Crafting Biotech NDAs
• Preparing A Promising Drug Candidate For ANDA Litigation (Part Two)

Leadership Lessons

• How To Build Invincible (Pharma) Companies

Ask The Board

• How Do You Build A System At A Life Sciences Company That Is “Fit For Purpose”?
• How Can We Get Away From Blaming Human Error Or Training During The RCA (Root Cause Analysis) Process Of CAPA (Corrective And Preventative Action) And Instead Get To The True Root Of The Issue?
• What Are The Current Trends For Where Compliance Reports In Small To Midsize Life Sciences Companies?